加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$2.02
−US$0.04 · -1.94%
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
收盘时
US$2.02
−US$0.04 · -1.94%
盘后
US$2.02
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
日内区间
当前US$2.02
52周区间
当前US$2.02
盘中时间采用ET。市场数据可能有所延迟。
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
日内区间
当前US$2.02
52周区间
当前US$2.02
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 302.2万 USD | 176.1万 USD | 130.2万 USD | 6996.3万 USD | 257.3万 USD |
| 销货成本 | — | — | — | 139.7万 USD | 140.2万 USD |
| 毛利 | 302.2万 USD | 176.1万 USD | 130.2万 USD | 6856.6万 USD | 117.1万 USD |
| 销售、一般及管理费用 | 685.2万 USD | 609.6万 USD | 890.3万 USD | 5671万 USD | 8074.8万 USD |
| 营业费用 | 723.6万 USD | 660.5万 USD | 982.5万 USD | 5790.3万 USD | 8074.8万 USD |
| 利息收入 | 15万 USD | — | 30万 USD | — | — |
| 利息支出 | 8000 USD | — | 20万 USD | — | 3291.7万 USD |
| 折旧和摊销 | 119.3万 USD | 50.9万 USD | 92.2万 USD | 120万 USD | 73.6万 USD |
| 营业利润 | −421.4万 USD | −484.4万 USD | −852.3万 USD | 1066.3万 USD | −7957.7万 USD |
| 净利润 | −56.9万 USD | −218.1万 USD | −1027.8万 USD | 1.12亿 USD | −1.72亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2022年5月9日 | 1:50 | — | — |
股票拆分 | 2011年10月3日 | 1:100 | — | — |
股票拆分 | 2009年7月27日 | 3:1 | — | — |
已生效 2022年5月9日
1:50
已生效 2011年10月3日
1:100
已生效 2009年7月27日
3:1
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI53.26万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF23.84万0.00%954亿 USD0.05%US$233.52-0.63%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM3万0.03%1.17亿 USD0.73%US$15.8484-0.58%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.04万0.00%61.81亿 USD0.26%US$68.32+0.06%
Dimensional - US Core Equity 2 ETFDFAC9941.560.00%885.96亿 USD0.21%US$45.31-0.04%
Dimensional - US Sustainability Core 1 ETFDFSU7440.720.00%23.92亿 USD0.15%US$48.13+0.04%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR6336.560.00%455.91亿 USD0.17%US$84.43-0.01%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACDimensional - US Sustainability Core 1 ETFDFSUU.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
